Last reviewed · How we verify
Védrines, Philippe, M.D. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| addition of azathioprine | addition of azathioprine | marketed | Purine analog immunosuppressant | Inosine monophosphate dehydrogenase (IMPDH), hypoxanthine-guanine phosphoribosyltransferase (HGPRT) | Immunology | |
| Switch to a second anti-TNF drug alone | Switch to a second anti-TNF drug alone | marketed | TNF inhibitor (class-level; specific agent varies) | TNF-alpha | Immunology / Rheumatology |
Therapeutic area mix
- Immunology · 1
- Immunology / Rheumatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- PIBD-Net · 1 shared drug class
- University Hospital Schleswig-Holstein · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Védrines, Philippe, M.D.:
- Védrines, Philippe, M.D. pipeline updates — RSS
- Védrines, Philippe, M.D. pipeline updates — Atom
- Védrines, Philippe, M.D. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Védrines, Philippe, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/v-drines-philippe-m-d. Accessed 2026-05-18.